BEMA(TM) Fentanyl Phase III Data Demonstrating Efficacy And Tolerability To Be Presented At American Pain Society Annual Meeting
May 15th 2008Drug InformationPain / Anesthetics
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and commercial partner Meda Pharmaceuticals will present, data from Phase III clinical pivotal trials for BEMA? Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid tolerant patients with cancer. The presentations will be made at the 27th Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
